Weight-Loss Drugs Protect Hearts
Two new studies found that weight-loss drugs like Wegovy and Ozempic may reduce heart damage after heart attacks. The research suggests these drugs could play a preventive role in cardiac care, especially for at-risk populations, opening new treatment pathways for cardio-metabolic health.
The cardiovascular benefits of semaglutide, the active ingredient in Wegovy and Ozempic, were previously established in the landmark SELECT trial. This study showed the drug reduced the risk of major adverse events like heart attack or stroke by 20% in patients with overweight or obesity and existing heart disease, but without diabetes. These heart-protective effects are not solely due to weight loss. The benefits appear quickly, sometimes within weeks, before significant weight reduction occurs. Researchers believe the drugs also reduce inflammation, lower blood pressure, and have direct positive effects on blood vessels. The newest research focuses on a dangerous complication called "no-reflow," which affects up to half of all heart attack patients. This occurs when tiny blood vessels in the heart remain constricted even after the main blocked artery has been cleared with emergency treatment. In recent animal studies led by the University of Bristol and University College London, GLP-1 drugs were found to prevent this "no-reflow" problem. The drugs appear to relax specific contractile cells called pericytes, allowing the small blood vessels to dilate and restore blood flow to the damaged heart muscle. This potential new use would complement existing post-heart attack treatments. Currently, emergency care involves procedures like angioplasty and stenting to open the main artery, followed by medications such as beta-blockers and ACE inhibitors to reduce the heart's workload and limit muscle damage. The promising results from these animal models have prompted calls for further studies in humans. Researchers suggest the findings could pave the way for paramedics to administer these drugs to heart attack patients as a standard part of emergency care in the future.
